ArticleCPT: pharmacometrics & systems pharmacology2022

Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis.

Nastya Kassir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.